Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice
2007

Bevirimat: A New HIV-1 Maturation Inhibitor

Sample size: 50 publication 10 minutes Evidence: high

Author Information

Author(s): Cheryl A. Stoddart, Pheroze Joshi, Barbara Sloan, Jennifer C. Bare, Philip C. Smith, Graham P. Allaway, Carl T. Wild, David E. Martin

Primary Institution: Gladstone Institute of Virology and Immunology, University of California at San Francisco

Hypothesis

Can bevirimat effectively reduce HIV-1 viral load and protect T cells in an animal model?

Conclusion

Bevirimat significantly reduces HIV-1 viral load and protects T cells in SCID-hu Thy/Liv mice.

Supporting Evidence

  • Bevirimat reduced viral RNA by more than 2 log10.
  • Treatment preserved immature and mature T-cell populations.
  • Bevirimat was effective against both wild-type and drug-resistant HIV-1.

Takeaway

Bevirimat is a new medicine that helps fight HIV by stopping the virus from maturing, which keeps the immune system stronger.

Methodology

Oral administration of bevirimat to HIV-1-infected SCID-hu Thy/Liv mice was used to assess its antiviral activity.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

SCID-hu Thy/Liv mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001251

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication